参考文献

1. N. Dyson, Chromatographic Integration Methods, Royal Society of Chemistry,Cambridge, 2nd edn, 1998.

2. A . Felinger, Data Analysis and Signal Processing in Chromatography,Elsevier, Amsterdam, 1998.

3. C. Burgess, D. G. Jones and R. D. McDowall, All You wanted to know about A/D converters but were afraid to ask, LC–GC Int., 1998, 10(12),5–8.

4. United States Pharmacopoeia <621> Chromatography, United States Pharmacopoeia Incorporated, Rockville, MD.

5. E uropean Pharmacopoeia, 2.2.46 Chromatographic Separation Techniques,European Council, Strasbourg.

6. R . D. McDowall, An evolutionary view of chromatography data systems used in bioanalysis, Bioanalysis, 2010, 2(2), 157–165.

7. ICH Q2(R1) Validation of Analytical Procedures: Text and Methodology,International Conference on Harmonisation, Geneva, 2005.

8. Food and Drug Administration, Draft Guidance for Industry Bioanalytical Method Validation, Silver Spring, MD, 2013.

9. European Medicines Agency, Guideline on Bioanalytical Method Validation,London, 2011.

10. 21 CFR 11, Electronic records; electronic signatures, final rule, US Government Publishing Office, Washington, DC, 1997.

11. EU GMP Annex 11 Computerised Systems, European Commission, Brussels,2011.

12. R . D. McDowall and C. Burgess, The Ideal Chromatography Data System for a Regulated Laboratory, Part 1: The Compliant Analytical Process,LCGC North Am., 2015, 33(8), 554–557.

13. R . D. McDowall and C. Burgess, The Ideal Chromatography Data System for a Regulated Laboratory, Part 2: System Architecture Requirements,LCGC North Am., 2015, 33(10), 782–785.

14. R . D. McDowall and C. Burgess, The Ideal Chromatography Data System for a Regulated Laboratory, Part 3: Essential Chromatographic Functions for Electronic Ways of Working, LCGC North Am., 2015, 33(12),914–917.

15. R . D. McDowall and C. Burgess, The Ideal Chromatography Data System for a Regulated Laboratory, Part 4: Assuring Regulatory Compliance,LCGC North Am., 2016, 34(2), 144–149.

16. R . D. McDowall, The Role of Chromatography Data Systems in Fraud and Falsification, LC·GC Eur., 2014, 27(9), 486–492.

17. Ohm Laboratories Warning Letter, Food and Drug Administration, 2009.

18. J. Liscouski, Laboratory and Scientific Computing–A Strategic Approach,Wiley, New York, 1995.

19. EU GMP Chapter 4 Documentation, European Commission, Brussels,2011.

20. G. P. Martin, K. L. Barnett, C. Burgess, P. D. Curry, J. Ermer, G. S. Gratzl,J. P. Hammond, J. Herrmann, E. Kovacs, D. J. LeBlond, R. LoBrutto, A.K. McCasland-Keller, P. L. McGregor, P. Nethercote, A. C. Templeton, D.P. Thomas and M. L. J. Weitzel, Lifecycle Management of Analytical Procedures:Method Development, Procedure Performance Qualification and Procedure Performance Verification, Pharmacopoeial Forum, 2012, 38(1).

21. ICH Q10 Pharmaceutical Quality Systems, International Conference on Harmonisation, Geneva, 2008.

22. EU GMP Chapter 1 Pharmaceutical Quality System, European Commission,Brussels, 2013.

23. EU GMP Chapter 6 Quality Control, European Commission, Brussels,2014.

24. FDA Guidance for Industry Out of Specification Results, Food and Drug Administration, Rockville, MD, 2006.

25. Good Automated Manufacturing Practice (GAMP) Guide Version 5, Tampa,FL, International Society for Pharmaceutical Engineering, 2008.

26. MHRA GMP Data Integrity Definitions and Guidance for Industry 2nd Edition, Medicines and Healthcare Products Regulatory Agency, London,2015.

27. Annex 5 Guidance on Good Data and Records Management Practices, WHO Technical Report Series No. 996, World Health Organisation, Geneva,2016.

28. FDA Draft Gudance for Industry Data Integrity and Compliance with cGMP,Silver Spring, MD, USA, 2016.